A high concentration of systemically administered Pip6a-PMO able to promote the inclusion of SMN2 exon 7 (hereby named Pip6a-PMO) has shown positive effects in a severe SMA mouse model [19]. The gene discussed is SMN2; the disease is proximal spinal muscular atrophy.